Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MediaAlpha heads into its October 28 earnings print with Goldman Sachs slashing its price target to within cents of the current price, activist holders on the register, and a modest short-interest decline that signals bears are quietly covering rather than pressing.
The catalyst for this week's tension is straightforward. Goldman's Eric Sheridan cut his target from $14.00 to $10.50 on October 14, leaving the stock at $10.47 with essentially no implied upside in the Goldman view, even while maintaining a Neutral rating. That move lands two weeks before the Q3 print and pulls the Street mean target down to $14.50, a level that now reflects a wide gap between the bulls and the newly cautious. RBC Capital and Keefe, Bruyette & Woods both carry Outperform ratings with targets of $15.00 to $17.00, and Canaccord sits at $17.00 Buy. JP Morgan holds Neutral at $15.00. The bull case rests on P&C vertical growth running at roughly 42% year-on-year and improving carrier profitability driving more acquisition spend. The bear case is the Health TV segment, which fell approximately 40% year-on-year, and Q4 guidance of $280 to $300 million that came in well below the $308 million the market had pencilled in. On valuation, the PE is running at 6.4x and EV/EBITDA at 4.4x, modest readings that partly explain why EPS surprise ranks in the 85th percentile and EPS momentum over 90 days scores in the 88th percentile. The stock is cheap relative to its earnings beat history, which is the core of the bull argument against a backdrop of soft guidance.
The lending market and short positioning tell a quiet story heading into the print. Short interest has fallen roughly 10% over the past week to 4.8% of the free float, a level that is meaningful but not extreme. Borrow availability is exceptionally loose, at close to 10 times the existing short position, meaning there is no structural squeeze pressure in the lending pool. Cost to borrow climbed around 42% on the week but remains very low in absolute terms at 0.82%. The options market is similarly measured: the put/call ratio is 0.14, slightly above its 20-day average of 0.11 and less than one standard deviation from normal. Bears are not loading up ahead of earnings through either the stock lending or options markets. The short score is sitting near 51, roughly the midpoint of the ORTEX scale, down from 52.2 a week ago. Positioning looks cautious rather than aggressive.
The ownership picture adds a layer of complexity that short interest alone does not capture. Two 13D activist filers are on the register. White Mountains Insurance Group holds 33% of the company and filed an amended 13D in May 2026, up from a prior stake of 31.7%. Eugene Nonko holds approximately 9.8% on a 13D basis, down from 10.8% at the time of his last filing in August. Both stakes are as-last-disclosed around the 5% threshold, and a holder dropping below 5% is not required to file again. Nonko has been selling in the open market through a pre-arranged 10b5-1 plan, with roughly 26,000 shares moved in the past 30 days. Co-founder Steven Yi also sold around 26,000 shares under a 10b5-1 plan in early October. These are planned disposals rather than discretionary conviction sells, but the net insider flow over 90 days is negative: roughly 289,000 shares sold for approximately $3.5 million. Divisadero Street Capital filed a fresh 13G in July 2026 at 5.8%, a passive stake that adds to the concentrated register.
One additional overhang is worth noting. ORTEX forecasts a 44% probability that MAX is deleted from the MSCI World Small, MSCI World IMI, MSCI USA Small, and MSCI USA IMI indices at the November 2026 Quarterly Review. The rank date is October 19, five days away. If the deletion is confirmed at the November 11 announcement, passive trackers would need to sell an estimated $5 million to $10 million across the affected indices, representing roughly 0.6 to 1.1 days of normal trading volume, with an effective date of December 1. That is not a large forced flow relative to the stock's liquidity, but it would represent incremental selling pressure arriving around the same time as the post-earnings tape sets.
The prior earnings print on July 29 produced a one-day move of minus 1.8% and a five-day move of minus 10.6%. With Goldman now anchoring its target at the current price, the next print on October 28 is less about whether P&C growth holds and more about whether Health TV stabilises and whether Q4 guidance revisions give the bulls enough to push back against the newest and most visible sceptic on the Street.
See the live data behind this article on ORTEX.
Open MAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
